Navigation Links
Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
Date:5/6/2008

United Therapeutics to Hold Investor Q&A Session Following Conclusion of

ATS Conference

SILVER SPRING, Md., May 6 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. today announced that data related to the four different routes of administration of the drug, treprostinil, for the treatment of pulmonary arterial hypertension will be presented at the annual meeting of the American Thoracic Society (ATS), to be held in Toronto, Ontario, beginning May 16th and ending May 21, 2008, including the first public presentation of the full data set from the TRIUMPH-1 study of inhaled treprostinil. Additional information concerning presentation topics and times may be accessed via the ATS conference website or at http://ir.unither.com/events.cfm.

United Therapeutics will host an investor Q&A session following the conclusion of the ATS conference at The Westin Harbour Castle, One Harbour Square, Toronto, Ontario, on May 21, 2008, at 5:00 pm EDT. Lewis Rubin, MD, Director of the Pulmonary Hypertension Program at the University of California San Diego, and Vallerie McLaughlin, MD, Director of the Pulmonary Hypertension Program at the University of Michigan, will participate in this Q&A session, which is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Lung Rx, Inc. is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of innovative therapeutic products. [uthr-g]


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
2. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
6. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
7. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
10. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
11. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):